A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Islatravir
Related studies linked through entity extraction aliases.
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
- Status
- WITHDRAWN
- Phase
- PHASE2
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
- Status
- WITHDRAWN
- Phase
- PHASE2
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
- Status
- TERMINATED
- Phase
- PHASE3
Islatravir and Methadone Pharmacokinetics (MK-8591-029)
- Status
- COMPLETED
- Phase
- PHASE1
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
- Status
- COMPLETED
- Phase
- PHASE2
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
- Status
- COMPLETED
- Phase
- PHASE1
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
- Status
- COMPLETED
- Phase
- PHASE2
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
- Status
- COMPLETED
- Phase
- PHASE2